Louis S Zarfas

Array ( [id] => 20135000 [patent_doc_number] => 20250242044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/073422 [patent_app_country] => US [patent_app_date] => 2025-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19073422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20057434 [patent_doc_number] => 20250195656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/064325 [patent_app_country] => US [patent_app_date] => 2025-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19064325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793367 [patent_doc_number] => 12234297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => IgE binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 18/792921 [patent_app_country] => US [patent_app_date] => 2024-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 70 [patent_no_of_words] => 29305 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18792921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816771 [patent_doc_number] => 20250074978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => ANTIBODIES FOR IL-17C [patent_app_type] => utility [patent_app_number] => 18/635426 [patent_app_country] => US [patent_app_date] => 2024-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20264 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18635426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809541 [patent_doc_number] => 12240912 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-03-04 [patent_title] => Methods of treating complement-mediated disease [patent_app_type] => utility [patent_app_number] => 18/618634 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 71 [patent_no_of_words] => 16825 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806938 [patent_doc_number] => 20230381271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY [patent_app_type] => utility [patent_app_number] => 18/361775 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19535486 [patent_doc_number] => 12128019 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-29 [patent_title] => Nanocomposite including abscisic acid-loaded collagen nanoparticles [patent_app_type] => utility [patent_app_number] => 18/210250 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 4439 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18210250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310726 [patent_doc_number] => 20230114626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 18/065921 [patent_app_country] => US [patent_app_date] => 2022-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497466 [patent_doc_number] => 20230220106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ANTIBODIES TARGETING 5T4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/062433 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18229091 [patent_doc_number] => 20230068085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => COMPOSITIONS AND METHODS FOR T CELL ENGINEERING [patent_app_type] => utility [patent_app_number] => 17/821664 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434414 [patent_doc_number] => 20230181708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => IPSC-BASED VACCINE AS A PROPHYLACTIC AND THERAPEUTIC TREATMENT FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/887444 [patent_app_country] => US [patent_app_date] => 2022-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530001 [patent_doc_number] => 20230235069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => TREATMENT OF ATOPIC DERMATITIS [patent_app_type] => utility [patent_app_number] => 17/818397 [patent_app_country] => US [patent_app_date] => 2022-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 132415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18242482 [patent_doc_number] => 20230074793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => TREATMENT WITH A BISPECIFIC ANTIBODY THAT BINDS CTLA4 AND PD1 [patent_app_type] => utility [patent_app_number] => 17/817845 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18553261 [patent_doc_number] => 20230251273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => METHOD FOR DETECTING INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/812058 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18486187 [patent_doc_number] => 20230213530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ASSESSMENT METHODS AND DIAGNOSTIC KIT FOR PREDICTING ACUTE ANTIDEPRESSANT RESPONSE AND REMISSION IN PATIENTS WITH DEPRESSIVE DISORDERS USING MULTIMODAL SERUM BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/855474 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403678 [patent_doc_number] => 20240287189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => ANTI-PDL1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/570249 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18570249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168050 [patent_doc_number] => 20230034659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => ANTI-PDL1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/842733 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056402 [patent_doc_number] => 20220387488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREATING HEMATOPOIETIC MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/742940 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17742940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807483 [patent_doc_number] => 20220259318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ANTIBODIES BINDING TO GPRC5D [patent_app_type] => utility [patent_app_number] => 17/586977 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19021298 [patent_doc_number] => 20240077469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY [patent_app_type] => utility [patent_app_number] => 18/272337 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272337 [rel_patent_id] =>[rel_patent_doc_number] =>)